GlobeNewswire

RapidFire Tools, Inc. Launches Its First Channel Programme, Offering Resources to Help MSPs Profit from GDPR Compliance

Dela

The Audit Guru for GDPR(TM) Partner Programme Includes Training, Onboarding Assistance, Marketing Materials, NFR Products, and an Online Management Portal

ATLANTA, April 16, 2018 (GLOBE NEWSWIRE) -- RapidFire Tools Inc., the developers of the powerful Network Detective suite of IT assessment and compliance tools, has launched an Authorized Reseller Partner Programme in coordination with its new Audit Guru for GDPR tool. The programme marks the first time RapidFire Tools is selling one of its products exclusively through a channel of MSP partners. The new product is designed to help organisations become compliant, and remain compliant, with the sweeping EU General Data Protection Regulation (GDPR). The regulation applies to any organisation that collects and processes personal information on people who reside within in the European Union. MSPs will have the option of simply reselling Audit Guru for GDPR to their end-user clients, or offering it along with value-added consulting and ongoing compliance management services. The GDPR takes effect on 25 May 2018.

The Audit Guru for GDPR Partner Programme is available to MSPs worldwide. While GDPR primarily affects MSPs in the EU, service providers in North America and other regions in the world whose clients service or do business with customers in the EU are also impacted. The new programme provides MSPs with everything they need to create a profitable GDPR compliance practice, including:

  • Extensive product training
  • A not-for-resale Audit Guru license for MSPs to use on their own networks
  • A second Audit Guru license to resell to their first client
  • A web-based product management portal to provision and manage the tool through a consolidated interface, or a "single pane of glass"
  • White-labelled marketing materials to help MSPs sell the new offering
  • One-on-one assistance to help MSPs onboard their first Audit Guru implementations
  • Unlimited technical support

"GDPR will have a considerable impact on IT everywhere," confirms Michael Mittel, president of RapidFire Tools. "The EU represents a significant percentage of the global economy, and any organisation on the planet that maintains personal information about individuals inside the EU are required to comply with these stringent new rules."

Audit Guru for GDPR is the first purpose-built software appliance to automatically collect the data required for a proper initial GDPR audit, as well as the required on-going compliance checks. The tool will automatically generate the documentation and reporting required under the standard. Audit Guru produces dynamic, step-by-step instructions and worksheets needed to complete the assessment process.

"Until now, our tools have been sold to MSPs for internal use as part of their business development and service delivery," explained Mittel. "This launch marks a paradigm shift, wherein we've designed a product that MSPs can sell directly to the network owner. We're relying 100 percent on our MSP channel customers, whose relationships in the SMB community will quickly bring Audit Guru to market."

In addition to healthy potential margins on the resale of Audit Guru appliance subscriptions, MSPs can gain additional revenue through value-added GDPR services, ranging from simple management of the appliances, up to fully managed and ongoing GDPR Compliance-as-a-Service offerings-all supported by RapidFire Tools' services. "The success of these MSPs is not left to chance. Our Authorized Reseller Partner Programme vests us in every aspect of the process, to ensure that MSPs are well positioned to profit," Mittel added.

"We believe every organisation is going to need a product like Audit Guru," said Mark Winter, RapidFire Tools' vice president of sales. "Everything in the programme is designed to help our MSPs get up-to-speed as quickly as possible to sell Audit Guru for GDPR into their existing client sites. MSPs who partner with us can create a lucrative enhancement to their portfolios, in addition to using the tool to land new clients."

Visit https://www.rapidfiretools.com/auditguru/ or call 678-323-1300, ext. 2.

About  RapidFire Tools

RapidFire Tools, Inc is the leading global supplier of business-building technology tools for MSPs to help them close more business, offer more services, keep more customers, and make more money. The company's offerings include: a complete set of IT Assessment, Documentation and Reporting tools; tools for IT Compliance Process Automation; and tools for Insider Cyber Threat Detection & Alerting. The new Audit Guru for GDPR tool helps MSPs and internal IT professionals automate and streamline the GDPR compliance process, to help align end-customers with the technology policies required by the new EU General Data Protection Regulation. European distributors for the Audit Guru for GDPR include: Achab (Italy), Prianto (UK), and Upstream (Denmark, Iceland, Finland, Norway, Sweden).

Contact: Bob Vogel
RapidFire Tools, Inc.
bvogel@rapidfiretools.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: RapidFire Tools, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum